This meeting was organised and funded by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. Prescribing information for the Novartis brands mentioned during this event are available in each recorded section.
The Novartis Haematology Masterclass is a multidisciplinary educational programme that has been running since 2014 and brings together haematology expertise to provide high-quality educational content. The Masterclass provides a platform for sharing the latest haematology clinical trial data, helping to support the implementation of best clinical practice.
Due to COVID-19 social distancing measures, the 2021 Haematology Masterclass was hosted virtually for the first time ever. Our expert speakers gave presentations on seven haematological disease areas; immune thrombocytopenia (ITP), chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML), myelofibrosis (MF), myelodysplastic syndrome (MDS) with iron overload (IOL), sickle cell disease (SCD) and CAR-T cell therapy in the management of R/R diffuse large B-cell lymphoma (DLBCL). The variety of topics covered is underpinned by the aim that the Novartis Haematology Masterclass should provide broad educational content for healthcare professionals with an interest in haematological disorders.
After viewing a video, you will be eligible to receive your CPD certificate.
In order to do so, please complete the steps below:
- If you have not already, please register an account in order to view each video by either clicking the blue buttons below, or signing up via the Novartis HCP Portal homepage.
- View a video presentation below and watch until the end.
- After 100% completion, a pop-up will appear to enable you to download your CPD certificate for each respective presentation.
Session 1: Immune Thrombocytopenia (ITP)
Dr Drew Provan and Dr David Kuter discuss and compare the latest 2019 guidelines for immune thrombocytopenia from the International Consensus Report (ICR) and American Society of Hematology (ASH)
Dr Vickie McDonald examines the ITP Registry in the UK and asks, what have we learnt?
Session 3: Acute Myeloid Leukaemia (AML)
Professor Sylvie Freeman provides an overview of minimal residual disease (MRD) in AML
Dr Richard Dillon explores the clinical utility of minimal residual disease (MRD) to support treatment decisions
Session 5: Myelodysplastic Syndrome (MDS) and Iron Overload (IOL)
Professor John Porter provides an overview of the mechanisms of IOL in MDS
Dr Jonathan Kell defines the problem of iron in MDS and looks at its impact
Dr Sally Killick discusses IOL monitoring and management in MDS
Dr Beth Payne presents case study examples of managing MDS in the clinic
Session 6: Sickle Cell Disease (SCD)
Professor Baba Inusa highlights the new service configuration for SCD across the UK and the implications of this for clinicians and patients
Dr Emma Drasar provides us with an update on the treatment landscape for SCD
Giselle Padmore-Payne presents practical examples from clinical case scenarios of managing SCD in an adult and a young adult
Session 7: CAR-T Cell Therapy in the Management of R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Dr Wendy Osborne describes third-line treatments available for DLBCL
Dr Andrea Kuhnl describes the long-term outcomes of CAR-T cell therapy
Dr Ben Uttenthal elaborates on the CAR-T referral process, including patient identification, eligibility criteria, and collaboration between referring and infusion centres
Haematology Masterclass has been running for the past six years and continues to deliver up-to-date and thought-provoking data in the field of haematology. Since 2014, the meeting has brought presentations from leading specialists in the UK and globally.
Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of healthcare professionals including registrars, nurses, pharmacists and consultants. We hope that you can join us for our next meeting in 2022.